DexCom, Inc. (DXCM)

Market Cap	45.29B
Revenue (ttm)	2.91B
Net Income (ttm)	341.20M
Shares Out	386.41M
EPS (ttm)	0.82
PE Ratio	142.94
Forward PE	120.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,319,699
Open	113.95
Previous Close	113.93
Day's Range	113.95 - 117.43
52-Week Range	66.89 - 134.77
Beta	1.09
Analysts	Buy
Price Target	135.40 (+15.52%)
Earnings Date	Apr 27, 2023

About DXCM

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 14, 2005
• Employees: 6,300
• Stock Exchange: NASDAQ
• Ticker Symbol: DXCM

Financial Performance

In 2022, DexCom's revenue was $2.91 billion, an increase of 18.84% compared to the previous year's $2.45 billion. Earnings were $341.20 million, an increase of 57.31%.

Analyst Forecast

According to 27 analysts, the average rating for DXCM stock is "Buy." The 12-month stock price forecast is $135.4, which is an increase of 15.52% from the latest price.

Price Target

$135.4

(15.52% upside)

Analyst Consensus: Buy